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likely to favour CBT-BN and so, current estimates may
be considered conservative.
MH2
COST-EFFECTIVENESS OF THE HIT
PROGRAMME IN PATIENTS WITH
SCHIZOPHRENIA AND PERSISTENT AUDITORY
HALLUCINATIONS
Stant A, Groen HJM,Wiersma D, Jenner J,TenVergert E
University Hospital Groningen, Groningen, Groningen,
Netherlands
OBJECTIVES: HIT, hallucination focused integrative
therapy, aims at the integration of cognitive behaviour
therapy with, among others, psycho-education and single-
family treatment. The present study focused on the cost-
effectiveness of the HIT programme in patients with
schizophrenia and a history of persistent auditory hallu-
cinations. METHODS: Patients were randomly assigned
to two treatment arms, HIT or care as usual (CAU). The
economic evaluation was performed from a societal per-
spective, costs, and effects of both patient groups were
registered prospectively during a period of 18 months.
The PANSS (Positive and Negative Syndrome Scale) was
used as the primary outcome measure in the cost-effec-
tiveness analysis. Bootstrap analyses provided additional
information on the skewly distributed costs. RESULTS:
Mean costs of patients in the HIT-group ($18,237) were
lower than the mean costs of patients who received CAU
($21,436). The total amount of costs was inﬂuenced sub-
stantially by the costs of sheltered living accommoda-
tions, admissions in psychiatric hospitals and medication
use. Costs of medication (about 10% of total costs) were
relatively high in the present study, which is most likely
due to increasing use of expensive atypical antipsychotics
in recent years. Results of the PANSS were in favour of
the HIT-group. The economic analyses indicated that the
HIT-program was cost-effective in the current situation.
In addition, bootstrap analyses illustrated the probable
range of future variations in cost differences (-$12,050
to +$6,637) between both groups. CONCLUSIONS: The
HIT-program appeared to be cost-effective in the current
situation. Additional analyses indicated that future appli-
cation of this intervention will in most cases lead to a
reduction of societal costs.
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HOSPITALIZATION RELATED TO ABUSE OF THE
ELDERLY WITH DEMENTIA AND OTHER
MENTAL HEALTH DISORDERS: RESOURCE USE
AND COSTS
O’Brien JA1, Pitoniak-Morse CA1, Caro JJ1, Jacobs LM2
1Caro Research Institute, Concord, MA, USA; 2University of
Connecticut Medical School, Farmington, CT, USA
OBJECTIVE: To examine the cost of hospital care for
medical problems resulting from abuse of those aged 
>= 65 years old with Alzheimer’s disease, dementia or
another mental health disorder. METHODS: Four years
of hospital discharge data (1997–2000) from 5 states
were examined using ICD-9 diagnosis and E-codes to
identify reason for admission due to abuse, and the rela-
tionship to the abuser. These databases were used to
examine type of injury and to develop inpatient hospital
costs, length of stay (LOS), physician visit proﬁles and
disposition patterns. Medicare national fee schedules
were used for physician-related unit costs. Cost estimates
include accommodations, ancillary and physician services
and are reported in 2003 US$. Hospital charges were
adjusted by means of a 0.61 cost-to-charge ratio.
RESULTS: Of the 277 abuse cases identiﬁed, 78% were
female. The mean age was 79 years, 83% were admitted
via the Emergency Room and 96% resided in the com-
munity at time of admission. The abuser was coded as
spouse/partner, child, sibling, other relative, non-relative
in 37%, 28%, 2%, 18% and 15% of the cases, respec-
tively. The mean LOS was 6 days (median: 4, range:
1–49). The mean cost per stay was $7,875 (median:
$3,797, range: $766–$174,580). The hospital case fatal-
ity rate was 3%. Among survivors, 43% were discharged
home (11% with home health care), 47% required addi-
tional sub-acute inpatient care (i.e., rehabilitation, skilled
nursing, intermediate care), 9% were transferred to a
mental health or a residential care facility and 1% signed
out against medical advice. CONCLUSIONS: Abuse of
the elderly has economic, as well as clinical consequences.
Although substantial, hospital costs are but one aspect of
the cost picture, as these patients require injury-related
medical care beyond the hospital stay. This analysis draws
attention to the potential clinical and economic ramiﬁca-
tions arising from caregiver burden.
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OBJECTIVES: To provide information on ﬁnancial,
social and mental burden borne by the families of chil-
dren with ADHD. METHODS: A pilot-tested question-
naire was sent to all members of the Flemish ADHD
society. Data are collected on disease severity (IOWA-
CRS (Conners Rating Scale)), health care utilization, use
of social care and other non-medical resources; and on
socio-demographic and economic characteristics of the
parents. Data of the ADHD-children are compared with
data of their siblings, for which similar data are collected.
RESULTS: A total of 656 questionnaires were returned
(response rate 38.5%), however, the IOWA-CRS was
completed in only 379 questionnaires. The mean age of
the children with ADHD is 10.04 (range 3–16) and mean
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age at diagnosis is 7.04 (range 2–14). 22.7% of the
ADHD-children exhibit a score below 15 on the IOWA-
CRS, 54.06% have a score between 15 and 22 and 22.7%
suffers from a severe form of ADHD with a score above
22 (maximum 30). The resource use of an ADHD-child
is signiﬁcantly higher compared to their siblings. Using
McNemar tests we found that ADHD-children are sig-
niﬁcantly more likely to have emergency department visits
(20.4% vs. 6.8%) and specialist visits (22% vs. 3.2%).
The severity of the disorder is positively related to med-
ication and specialist use (Wilcoxon Signed Rank Test).
Parents stay signiﬁcantly more often home from work 
for their ADHD-child (10.6% vs 2.4%) and signiﬁcantly
more children with ADHD miss a year at school (17.2%
vs. 4.3%) or go to a special school for children with learn-
ing disabilities (10% vs. 0.9%). CONCLUSION: Child-
hood ADHD results in signiﬁcantly higher use of health
care and adversely affects school attainments and parents’
productivity. This puts a heavy burden on the family.
Nevertheless we have to take into consideration we have




SHORT AND LONG TERM COST-EFFECTIVENESS
ANALYSIS OF CLOPIDOGREL IN PATIENTS
WITH ACUTE CORONARY SYNDROME
WITHOUT ST- SEGMENT ELEVATION (ACS) IN
SCANDINAVIAN COUNTRIES
Lindgren P1, Jönsson B2, Spiesser J3, Carita P3, Gabriel S3
1Institute of Environmental Medicine, Karolinska Institutet,
Uppsala, Sweden; 2Stockholm Health Economics, Stockholm,
Sweden; 3Sanoﬁ-Synthelabo Recherche, Bagneux, France
OBJECTIVE: The CURE trial demonstrated the superior
efﬁcacy of clopidogrel compared to placebo, both groups
receiving standard therapy including ASA in prevent-
ing myocardial infarctions, strokes, and cardiovascular
deaths in patients with ACS. The purpose of this analy-
sis was to evaluate short and long term cost-effectiveness
of clopidogrel in 4 Scandinavian countries: Denmark,
Finland, Norway and Sweden. METHODS: A within
trial analysis was performed based on data collected
alongside the clinical trial (hospitalizations, procedures,
comedications, and study drugs). Hospitalizations costs
were evaluated through a Diagnosis Related Group
approach. Cost-effectiveness was expressed as the cost
per event avoided. A long term model using Swedish epi-
demiological data (national registry) was also performed
to capture the long term beneﬁts of clopidogrel. A
Markov model with six states (at risk, ﬁrst year with
stroke, following years with stroke, ﬁrst year with new
MI, following years with new MI and death) was used.
Cost-effectiveness was expressed as the cost per life year
gained (LYG). Costs used were for the 2001 year. Both
costs and beneﬁts were discounted at 3%. RESULTS:
Occurrence of the composite outcome was signiﬁcantly
lower in the clopidogrel arm (11.14% versus 13.15%).
Patients in the clopidogrel arm have on average higher
costs than patients treated with ASA alone: the net incre-
mental cost ranges from €289 to €488. This leads to a
cost per event avoided ranging from €13,391 to €24,700.
The long term model predicts an incremental survival of
0.117 years for an incremental direct medical cost ranging
from €64 to €488 per patient. The cost per LYG ranges
from €549 to €4003. When indirect costs are included this
ratio is €2181 in Finland and clopidogrel is cost saving
in other countries. CONCLUSION: Both short and long
term analyses conclude that clopidogrel is very cost effec-
tive in the treatment of patients with ACS.
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PREVENTION OF ISCHEMIC EVENTS IN HIGH
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OBJECTIVES: To determine the incremental cost per life
year saved (ICLYS) of clopidogrel versus ASA in sec-
ondary prevention of ischemic stroke (IS), myocardial
infarction (MI), or vascular death (VD) in 2 high risk sub-
groups of the CAPRIE trial (patients with prior IS or MI
to index event, and atherothrombotic patients treated for
hypercholesterolemia and/or with diabetes) in Belgium.
METHODS: A Markov model designed with 7 clinical
states calculated ICLYS as the cost needed to achieve an
extra life year with clopidogrel compared to ASA. The
model combined rates of clinical outcomes calculated
from the CAPRIE database and survival data derived
from the Saskatchewan database. The costing of events,
including acute care and follow-up, was performed using
ofﬁcial data (DRG systems), tariffs and/or charges (physi-
cians fees, examinations, lab tests), divided in acute costs
and costs per subsequent 6 month follow-up periods. The
economic analysis was performed from the health care
system perspective using only direct medical costs for 
2-year treatment. A discount rate of 3% was applied to
costs and lifetime effects. RESULTS: In ﬁrst subgroup
(prior MI or IS), 27 additional atherothrombotic events
(14 MI, 12 IS, 1VD) were avoided per 1000 patients
treated with clopidogrel versus ASA with a gain in 
survival of 119 years. In second subgroup (hypercholes-
terolemia and/or diabetes), 28 additional atherothrom-
botic events (14 MI, 8 IS, 6VD) were avoided with a gain
in survival of 130 years per 1000 patients. The incre-
mental cost of the clopidogrel arm compared to ASA was
€702 in ﬁrst group and €771 in second group. The ICLYS
was very similar in the 2 subgroups: €5900 and €5930
respectively. Results were robust under a wide variation
